Metabolic Barriers to T Cell Function in Tumors
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
The metabolic programs that drive T cell functions are exquisitely sensitive to cell intrinsic and extrinsic factors, allowing T cells to respond in a fine-tuned manner to a variety of immune challenges and conditions. However, many of the factors essential for effector T cell function are perturbed in the tumor microenvironment, where oncogenic mutations drive unrestrained cancer cell growth that leads to excess nutrient consumption, excess waste excretion, and insufficient oxygen delivery. This imposes metabolic constraints on infiltrating cells that result in dysfunction and loss of potential antitumor activity in both naturally occurring as well as tailored T cells introduced as part of immunotherapy. In this review, we highlight the metabolic properties that characterize tumor-infiltrating T cells, the barriers within the metabolic landscape of the tumor microenvironment, and the opportunities and challenges they present in development of new cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is known that mesothelioma cells increase the expression of L-type Amino acid Transporter 1 (LAT1), depriving T-cells of amino acids, such as arginine and tryptophan, which are essential for T-cell function and proliferation [121].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mesothelioma cells could also inhibit T-cell glycolysis and functions, increasing the levels of indoleamine-pyrrole 2,3-dioxygenase (IDO), which degrades tryptophan into kynurenine, a well-known immunosuppression factor [121,123,124].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the mesothelioma microenvironment, the availability of glucose is critical, and competition for this molecule impacts on T-cell function and the recruitment of immune infiltrating cells, promoting angiogenesis [119,120,121,122].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [121]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 2×
“required for maintaining the TCA cycle as well as a vital source for lipid synthesis through reductive carboxylation in hypoxic cancer cells (1) and Teff cells (2).”
BackgroundCommensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549 · cited 1×
“Both in vitro and in vivo studies in the gut suggest short chain FAs can induce Treg cell differentiation (67, 68), although this may be through changes in G protein–coupled receptor-mediated signaling rather than direct use as a metabolic fuel.”
BackgroundThe Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413 · cited 1×
“Both in vitro and in vivo studies in the gut suggest short chain FAs can induce Treg cell differentiation (67, 68), although this may be through changes in G protein–coupled receptor-mediated signaling rather than direct use as a metabolic fuel.”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“Consider PD-1 blockade, which has yielded promising results in many cancer patients, but not so in a sizeable population of patients (83).”
BackgroundKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · cited 1×
“Increased HIF1a activity promotes aerobic glycolysis and reduces OXPHOS by upregulating pyruvate dehydrogenase kinase (PDK1) and lactate dehydrogenase A (26, 27), effectively shunting pyruvate away”
BackgroundMetabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172 · cited 1×
“Hypoxia and upregulation of HIF1a in tumors are both associated with poor clinical outcomes in cancer patients (69).”
BackgroundFunctional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046 · cited 1×
“Additionally, lactate has been shown to stabilize HIF1a in macrophages (74), and can be predicted to have similar effects in T cells.”
BackgroundIschaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907
Understanding the Intersections between Metabolism and Cancer Biology
Vander Heiden, M. G., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,293
Research works printed but not linked: 3
- Michalek RD Gerriets VA Jacobs SR Macintyre AN MacIver NJ Mason EF Sullivan SA Nichols AG Rathmell JC 2011 Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets The Journal of Immunology 186 3299 3303 21317389 PMC3198034
- Gerriets VA Kishton RJ Johnson MO Cohen S Siska PJ Nichols AG Warmoes MO de Cubas AA MacIver NJ Locasale JW Turka LA Wells AD Rathmell JC 2016 Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression Nat Immunol 17 1459 1466 27695003 PMC5215903
- Frauwirth KA Riley JL Harris MH Parry RV Rathmell JC Plas DR Elstrom RL June CH Thompson CB 2002 The CD28 Signaling Pathway Regulates Glucose Metabolism Immunity 16 769 777 12121659
Cited by
Items 101–200 of 223
Ionic Regulation of T-Cell Function and Anti-Tumour Immunity
Ginefra, P., Hope, H. C., Spagna, M., Zecchillo, A., & Vannini, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413668 · Cited by 20
“, adenosine or kynurenine) have been deeply studied during the last decade [5,6], and a myriad of promising interventions has been developed to overcome these metabolic barriers and to boost anti-tumour T-cell responses [7,8].”
BackgroundMetabolic Regulation of CD8 + T Cells: From Mechanism to Therapy
Zheng, Y. Y., Wang, X., & Huang, M. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0040 · Cited by 20
“The past decades have witnessed the increasing recognition that CD8 + T cell metabolism in the TME is often adapted to diminish antitumor immune responses and thereby to allow evasion from immune surveillance (1, 13, 72, 107, 124, 140).”
Catala, A., & Ahmad, U. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89926 · Cited by 19
New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy
Oberholtzer, N. P., Quinn, K. M., Chakraborty, P., & Mehrotra, S. (2022) · Cells · doi:10.3390/cells11040708 · Cited by 19
“As has been well established, tumor cells undergo a metabolic shift from OXPHOS to aerobic glycolysis, leading to the consumption of environmental glucose and glutamine [116], and the depletion of these critical nutrients in the TME renders conventional T cells unresponsive or functionally exhausted [113,117].”
BackgroundLipid metabolic features of T cells in the Tumor Microenvironment
Lou, W., Gong, C., Ye, Z., Hu, Y., Zhu, M., Fang, Z., & Xu, H. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01705-y · Cited by 19
Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers
Moss, D., McCann, C. K., & Kerr, E. M. (2022) · Science Signaling · doi:10.1126/scisignal.abj3490 · Cited by 18
“KRAS-driven glutamine uptake and metabolism in tumor cells deplete glutamine from the TME (21, 133, 290), inhibiting T cell activation and cytokine production, contributing to the establishment of a tolerogenic TME (290, 291).”
BackgroundChimeric Antigen Receptor T-Cell Therapy for Solid Tumors
Wala, J. A., & Hanna, G. J. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.009 · Cited by 18
Jahangiri, S., & Yu, F. T. H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030411 · Cited by 18
“Additionally, unrestrained cancer cell proliferation results in increased hypoxia and acidosis, which alters T-cell metabolism, TCR engagement, function, and proliferation [57].”
BackgroundValidation of a method evaluating T cell metabolic potential in compliance with ICH Q2 (R1)
Mercier‐Letondal, P., Marton, C., Godet, Y., & Galaine, J. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02672-7 · Cited by 18
Zhang, C., Zhou, L., Li, S., Zhao, J., Meng, X., Ma, L., Wang, Y., Li, C., Zheng, L., & Ming, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215918 · Cited by 18
CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead
Shaer, N. S. H. A., Masoud, I., Tleyjeh, A., Al-Attas, A. A., Al-Attas, M. A., Khan, M. I., & Yaqinuddin, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1796675 · Cited by 17
The new era of lung cancer therapy: Combining immunotherapy with ferroptosis
Li, Y., Tuerxun, H., Zhao, Y., Liu, X., Li, X., Wen, S., & Zhao, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104359 · Cited by 17
Immunometabolism of regulatory T cells in cancer
Galgani, M., Bruzzaniti, S., Rocca, C. L., Micillo, T., de Candia, P., Bifulco, M., & Matarese, G. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100936 · Cited by 17
Tanaka, I., Koyama, J., Itoigawa, H., Hayai, S., & Morise, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249237 · Cited by 16
“Among these factors, the metabolic reprogramming of glycolysis and glutaminolysis in tumor cells has emerged as a current area of focus for explaining the limited response to immunotherapy (30, 31).”
BackgroundGao, B., Wang, Y., & Lu, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-28436-z · Cited by 16
The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications
Jiao, Z., Pan, Y., & Chen, F. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00645-2 · Cited by 16
“As previously discussed, metabolic constraints on infiltrating T cells that are imposed by tumor cells, including decreased mTOR activity and a low glycolytic rate, can result in T-cell hyporeponsiveness [225].”
BackgroundMicroRNA-mediated metabolic regulation of immune cells in cancer: an updated review
Khameneh, S. C., Razi, S., Lashanizadegan, R., Akbari, S., Sayaf, M., Haghani, K., & Bakhtiyari, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424909 · Cited by 14
“The metabolic activity of tumor cells may impact the immune system by producing metabolic by-products that signi fi cantly affect immune cell activation, fi tness, and effector function, or by competing fi ercely for vital resources (such as glucose, glutamine, lipids, and amino acids) (4, 5).”
BackgroundAdvanced nanomaterials for enhanced immunotherapy via metabolic regulation
Li, X., Ding, B., Zheng, P., Ma, P., & Lin, J. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215540 · Cited by 14
Glutamine promotes human CD8+ T cells and counteracts imiquimod-induced T cell hyporesponsiveness
Bopp, L., Martinez, M. L., Schumacher, C., Seitz, R., Arana, M. H., Klapproth, H., Lukas, D., Oh, J. H., Neumayer, D., Lackmann, J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109767 · Cited by 13
Endocrine Adverse Events Related with Immune Checkpoint Inhibitors: An Update for Clinicians
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Immunotherapy · doi:10.2217/imt-2019-0132 · Cited by 13
Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma
van Bruggen, J. A. C., Martens, A. W. J., Tonino, S. H., & Kater, A. P. (2020) · Cancers · doi:10.3390/cancers12123837 · Cited by 14
Ton, N. Q. C., & Park, P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108015 · Cited by 12
Zhang, Z., Mao, M., Wang, F., Zhang, Y., Shi, J., Chang, L., Wu, X., Zhang, Z., Xu, P., & Lu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1164669 · Cited by 12
“Metabolic reprogramming, for example, is the backbone of T cell differentiation and activation, as the transition from quiescence to activation, proliferation, differentiation and infiltration bears a heavy energy burden (44, 45).”
BackgroundBeadnell, T. C., Fain, C. E., Vivian, C. J., King, J. C., Hastings, R. C., Markiewicz, M. A., & Welch, D. R. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165648 · Cited by 12
Kwok, H., Yang, J., & Lam, D. C.-L. (2023) · Cancers · doi:10.3390/cancers15102749 · Cited by 11
“The altered metabolic landscape of the tumor microenvironment may also inhibit the infiltration of various immune cells [86].”
BackgroundGuo, Q., Qiu, P., Pan, K., Liang, H., Liu, Z., & Lin, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-72406-y · Cited by 11
Predicting the Proliferation of Tongue Cancer With Artificial Intelligence in Contrast-Enhanced CT
Sun, T., Mao, L., Chai, Z., Shen, X., & Sun, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841262 · Cited by 11
“It has a great impact on the immune microenvironment and immunotherapy by creating more mutations with neoantigens and damaging the function of T cells to help tumor escape immunity (4, 23, 24).”
BackgroundSimula, L., Ollivier, E., Icard, P., & Donnadieu, E. (2022) · Cells · doi:10.3390/cells11111854 · Cited by 11
“Based on in vitro data, we can speculate that the reduced availability of glucose and the consequent reduction in glycolytic rates observed in tumor-infiltrating T cells [96] may be associated with reduced motility.”
Giehl, E., Kosaka, H., Liu, Z., Feist, M., Kammula, U. S., Lotze, M. T., Ma, C., Guo, Z. S., & Bartlett, D. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.610042 · Cited by 11
Nie, Q., Cao, H., Yang, J., Liu, T., & Wang, B. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102021 · Cited by 10
“The differentiation, proliferation and infiltration of T cells require a large amount of energy supply [30].”
BackgroundMetabolism and Immune Suppressive Response in Liver Cancer
Caini, P., & Carloni, V. (2025) · Biomedicines · doi:10.3390/biomedicines13061461 · Cited by 10
“Hence, we can infer that a reduction in glucose is detrimental for Teff-cell proliferation and cytokine production, but it is favorable for Treg cells [121–124].”
Lipid Metabolism in Tumor-Infiltrating T Cells
He, S., Cai, T., Yuan, J., Zheng, X., & Yang, W. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6785-2_10 · Cited by 10
Wang, Y., Smith-Oliver, M. R., Ruiz, J., Liu, Y., Kucera, G. L., Topaloĝlu, Ü., Chan, M. D., Li, W., Su, J., & Xing, F. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.01.016 · Cited by 10
Ferroptosis in Cancer Immunotherapy—Implications for Hepatocellular Carcinoma
Kusnick, J., Bruneau, A., Tacke, F., & Hammerich, L. (2022) · Immuno · doi:10.3390/immuno2010014 · Cited by 9
“With better understanding of metabolic features of the TME and tumor-infiltrating lymphocytes (TILs), new opportunities to improve and promote appropriate immune cell function arise [215].”
BackgroundChanges in tumor and cardiac metabolism upon immune checkpoint
Leven, A., Wagner, N., Nienaber, S., Messiha, D., Tasdogan, A., & Ugurel, S. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01092-8 · Cited by 8
“Due to the high metabolic activity of cancer cells and the limited vascularization, cancer and immune cells are forced to compete for nutrients and oxygen [148].”
Suresh, P. K., Banerjee, A., & Singh, P. (2023) · OpenNano · doi:10.1016/j.onano.2023.100134 · Cited by 8
Terapi L-Ascorbic Acid 10% dan Glutation 2% Dibandingkan dengan Hidrokuinon 4% pada Pasien Melasm
Rinandari, U., Dewi, P. F., Kusumawardani, A., Irawanto, M. E., & Mochtar, M. (2021) · Jurnal Health Sains · doi:10.46799/jhs.v2i8.256 · Cited by 8
“L-ascorbic acid merupakan bentuk aktif vitamin C dan dikenal sebagai agen antipigmentasi (Sugiura & Rathmell, 2018).”
BackgroundFerroptosis at the intersection of radiotherapy and immunotherapy
Wei, G.-X., Zhao, Y., Tang, R., Shi, H., & Li, Z. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10306-x · Cited by 8
“Previous studies have demonstrated that certain immune cells in the TME, including macrophages, Tregs, and dendritic cells (DCs), share similar metabolic regulation signals and growth characteristics with tumor cells [161–163].”
Molecular and temporal control of restimulation-induced cell death (RICD) in T lymphocytes
Lee, K. P., Epstein, B. E., Lake, C. M., & Snow, A. L. (2023) · Frontiers in Cell Death · doi:10.3389/fceld.2023.1281137 · Cited by 7
“Nutrient deprivation, hypoxia and high lactate levels within the tumor microenvironment are known to debilitate T cell function (Sugiura and Rathmell, 2018), but ramifications for T cell survival in an antigen-dense environment remain unclear.”
Egan, D., Glennon, K., Treacy, A. D., Fabre, A., McCormack, J., Hill, S., Morrison, R. D., Zhernovkov, V., Liebler, D. C., Kölch, W., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00973-y · Cited by 7
“Astumors progress, they establish a hostile microenvironment-characterized by nutrient scarcity, waste accumulation, acidity, and hypoxia-thatrestrictsTcellactivity 48 .”
Zhang, Y., Xu, H., Han, X., Yu, Q., Zheng, L., & Xiao, H. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102267 · Cited by 7
Xu, K., Shyu, A., & Li, M. O. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.016 · Cited by 6
Zheng, Z. R., Ma, K., Li, H. Y., & Meng, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110982 · Cited by 6
Role of CD4+ T-cells in the pathology of non-alcoholic fatty liver disease and related diseases
Seike, T., Mizukoshi, E., & Kaneko, S. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.46 · Cited by 6
The Cancer Immunotherapy Revolution: Mechanistic Insights
Fink, P. J. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1790024 · Cited by 6
“T cell repertoire and tumor mutation profiles aside, Sugiura and Rathmell discuss the metabolic barriers to efficacious T cell function erected by the acidic and hypoxic tumor microenvironment (TME) that is stingy on nutrients and awash with metabolic waste products (3).”
BackgroundLiu, J., Hong, S., & Gu, K. (2025) · Discover Oncology · doi:10.1007/s12672-025-03779-3 · Cited by 5
“Currently, accumulating evidence strongly suggests that the function of activated T-cell lymphocytes is highly reliant on cellular energy metabolism [5, 7].”
Thermogenic T cells: a cell therapy for obesity?
Beier, U. H., Baker, D. J., & Baur, J. A. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00034.2022 · Cited by 5
Huerta, D. A., Pizzo, R. D., Kowar, A., Baig, A. H., Palazzo, G., Stepanova, E., Ramirez, C. C. A., D’Agostino, S., Ratto, E., Pechincha, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59986-7 · Cited by 4
Enwere, M., Irobi, E., Chime, V., Ezeogu, A., Onu, A., Hussein, M. T. E., Ogungbade, G. O., Davies, E., Omoniwa, O., Omale, C., et al. (2025) · Onco · doi:10.3390/onco5030043 · Cited by 4
“Tumors consume vast quantities of glucose and glutamine, creating a nutrient-depleted, acidic, and hypoxic environment that cripples effector immune cell function while favoring immunosuppressive cells [94,95].”
Immunometabolic Regulation of Anti-Tumor T-Cell Responses by the Oncometabolite D-2-Hydroxyglutarate
Böttcher, M., & Mougiakakos, D. (2019) · Immunometabolism · doi:10.20900/immunometab20190007 · Cited by 4
“The sensitivity of T-cell metabolic programs to intrinsic and extrinsic factors for their functional responses have been shown to be hijacked by a variety of tumors (Figure 2B) including AML and glioma [32,33].”
BackgroundBioengineering tools for probing intracellular events in T lymphocytes
Zhang, X., Mariano, C. F., Ando, Y., & Shen, K. (2020) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1510 · Cited by 4
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript for harnessing T cell immunity against infectious diseases and cancer (Sugiura & Rathmell, 2018).”
BackgroundProspects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma
Tietze, S., Michen, S., Schackert, G., & Temme, A. (2021) · Innovative Surgical Sciences · doi:10.1515/iss-2020-0034 · Cited by 4
“Competition for glucose, lactate production and subsequently the generation of an acidic tumor microenvironment, may modulate metabolism of TILs, affecting their immune effector functions, their exhaustion and/or their survival [56].”
BackgroundShariatzadeh, M., Lopes, A. G., Glen, K. E., Sinclair, A. H., & Thomas, R. J. (2021) · Biotechnology Progress · doi:10.1002/btpr.3205 · Cited by 4
“As a result, Glut1 blockade could be an effective strategy to generate more selective sub-populations of T-cells such as long-lived TSCM.3,32 Increased expression of Glut1 and glucose uptake are associated with higher cellular growth and proliferation in thymocytes.33,34 Following immune activation, metabolic rates si…”
BackgroundZhou, Y., Zhu, J., Gu, M., & Gu, K. (2023) · Journal of Oncology · doi:10.1155/2023/6851036 · Cited by 4
“Te infammatory TME is also verifed from cell levels.”
BackgroundInfluentialMetabolism of tumor infiltrating T cells
Ertl, H. C. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1711328 · Cited by 3
“Within the tumor microenvironment (TME) T cells and tumor cells compete for glucose, with the latter commonly outcompeting the former (12) leading to their functional impairments (13, 14).”
Sui, D., Liu, F., Zheng, L., Yu, S., Ding, Z., Ren, X., Gao, J., Wang, W., & Yang, L. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105182 · Cited by 3
Yi, R., Zhang, Z., Yang, Y., & Zhu, H. (2026) · Cancer Innovation · doi:10.1002/cai2.70053 · Cited by 3
Mun, H. B., Kwon, W. S., Park, C. H., Koo, H., Jang, J., Yoon, B. G., Park, J., Moon, Y. J., Lee, C., Jeung, H., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-05006-4 · Cited by 3
“…metabolic states can influence anti-tumor immunity by altering nutrient availability, redox balance, lipid handling, and the accumulation of immunomodulatory metabolites within the tumor microenvironment, thereby affecting T-cell fitness, infiltration, and responsiveness to immunotherapy [54–58].”
Cancer Metabolism and Aggressive Tumor Behavior
Chaudhary, S., Shah, A., Pothuraju, R., Lakshmanan, I., Ganti, A. K., & Batra, S. K. (2022) · Springer eBooks · doi:10.1007/978-981-16-6226-3_2 · Cited by 3
Mezher, R. C., Azari, H., Khayami, R., Fiuji, H., Alizadeh, F. L., Goshayeshi, L., Rajabian, M., Gataa, I. S., Hassanian, S. M., & Avan, A. (2025) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.70042 · Cited by 3
Role of Interferon in Cancer Metabolism
Chandel, V., & Kumar, D. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92020 · Cited by 3
“Bioenergetic pathways include glucose metabolism, tricarboxylic acid cycle (TCA), FAO, OXPHOS, electron transport chain (ETC), and pentose phosphate pathway (PPP) [55].”
BackgroundDevelopment of therapeutic cancer vaccines based on cancer immunity cycle
Zhang, J., Zheng, Y., Xu, L., Gao, J., Ou, Z., Zhu, M., & Wang, W. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1134-6 · Cited by 2
Lin, C., Luo, T., Wu, M. Y., Li, F., Nunes, L., Mezheyeuski, A., Hammarström, K., Isaksson, A., Ljuslinder, I., Uhlén, M., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100268 · Cited by 2
“79 Furthermore, the low expression of PTEN combined with PI3K pathway activation observed in class 2 tumours has previously been linked to the obstruction of T-cell infiltration in multiple cancers.”
Qian, Z.-Y., Deng, Y., Xi, M., Zhang, X. M., Sun, H., Mao, M., Luo, X.-J., Li, M., Zhang, Q., Chen, B., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1449 · Cited by 2
Wang, M., Dong, W., Chen, J., Zhou, Z., Fu, S., Wu, T., Jiang, H., Wang, Z., Zhong, Z., & Zhong, Y. (2026) · Advanced Science · doi:10.1002/advs.75651 · Cited by 2
“Within the complex TME of solid tumors, severe hypoxia serves as a critical signal driving the dysfunctional remodeling of T-cell mitochondria, profoundly impacting the durability of anti-tumor immune responses [ 50 ].”
Waseem, S., Zhan, J., & Xiao, X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125373 · Cited by 3
“Additionally, metabolic competition high tumor glycolysis creating lactate-rich, glucose-poor microenvironments impairs effector T-cell function and promotes resistance [160].”
Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting
Santis, F. D., Vecchio, M. D., Castagnoli, L., de Braud, F., Cosimo, S. D., Franceschini, D., Fucà, G., Hiscott, J. B., Malmberg, K., McGranahan, N., et al. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.10.005 · Cited by 2
Cell metabolism: Functional and phenotypic single cell approaches
Biasi, S. D., Gigan, J. P., Borella, R., Santacroce, E., Tartaro, D. L., Neroni, A., Paschalidis, N., Piwocka, K., Argüello, R. J., Gibellini, L., et al. (2024) · Methods in cell biology · doi:10.1016/bs.mcb.2024.02.024 · Cited by 2
Impact of respiratory viral infections on tumor progression in Non-Small-Cell Lung Carcinoma (NSCLC)
Angrini, M. (2021) · theses.fr (ABES) · doi:10.70675/9c027d88z3675z44adza870z1802353e674a · Cited by 2
Unspecific CTL Killing Is Enhanced by High Glucose via TNF-Related Apoptosis-Inducing Ligand
Yang, W., Denger, A., Diener, C., Küppers, F., Soriano‐Baguet, L., Schäfer, G., Yanamandra, A. K., Zhao, R., Knörck, A., Schwarz, E. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.831680 · Cited by 1
“Glucose metabolism and the proper access to glucose are essential to maintain CTL effector functions, especially their killing function (8).”
BackgroundTumor-Draining Lymph Node-Targeted Electrochemotherapy: A Hypothesis for In Situ Cancer Vaccination
Mahdavi, R., Ataee, H., Dehkordi, A. A., Shabani, M., Hemati, A., & Abdolahad, M. (2025) · Biomedicines · doi:10.3390/biomedicines13112746 · Cited by 1
Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species
Wesolowski, A. J., Pillay, A. M., Vardaka, P., Nasrallah, R., GREAVES, R., Li, H., Loffreda, I., Jenkins, C., James, A. M., Nuebling, A., et al. (2026) · Science · doi:10.1126/science.adz8203 · Cited by 1
Bartusik‐Aebisher, D., Raj, D. R. J., Wilk, I., & Aebisher, D. (2026) · Molecules · doi:10.3390/molecules31173124 · Cited by 1
“The excess of lactate, depletion of tryptophan, and hypoxia provide a metabolically hostile and ideal environment to maintain immune exclusion and continue being resistant to the checkpoint blockade [50].”
Sutanto, H., Fetarayani, D., Rachma, B., & Caesario, J. (2026) · BMJ Immunology · doi:10.1136/bmjimm-2025-000010 · Cited by 1
Tumor-Induced Metabolism and T Cells Located in Tumor Environment
Iranparast, S., Tayebi, S., Ahmadpour, F., & Yousefi, B. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200720010647 · Cited by 1
Integrated Molecular Profiling as an Approach to Identify PI3K Inhibitor Resistance Mechanisms
Michmerhuizen, N. L., Wang, J., & Brenner, J. C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92875 · Cited by 1
Modeling of the Tumor Microenvironment in Tumor Organoids
Shelkey, E., Dominijanni, A. J., Forsythe, S. D., Oommen, D., & Söker, S. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166013-00279 · Cited by 1
Monajjemi, M., Mollaamin, F., Mohammadi, S., & Shahriari, S. (2025) · Revista Colombiana de Ciencias Químico Farmacéuticas · doi:10.15446/rcciquifa.v53n3.119213 · Cited by 1
“There are huge information indicating that metabolic conversions in the cancer tumors might be converted to anti-immune metabolism and consequently ruin antitumor immunity [33-35].”
Understanding Metabolic Adaptation Of T Cells During Activation And Nutrient Limitation
Ecker, C. (2018) · ScholarlyCommons (University of Pennsylvania) · Cited by 1
Metabolic modulation of tumors with engineered bacteria for immunotherapyPreprint
Geiger, R., Canale, F. P., Basso, C., Antonini, G., Perotti, M., Li, N., Sokolovska, A., Neumann, J., James, M., Geiger, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-500473/v1 · Cited by 1
Immunotherapeutic Targeting Of Lineage Restricted Oncoproteins In Immunogenically Silent Tumors
Yarmarkovich, M. (2019) · ScholarlyCommons (University of Pennsylvania)
Papel da enzima 6-fosfofruto-2-quinase / frutose-2,6-bifosfatase (PFKFB3) em células T reguladoras
Rosa, M. H. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2020.tde-18082020-213816
Mikhailova, A. (2018) · theses.fr (ABES) · doi:10.70675/fecf1cb4z7765z4757zb68ez0f234fe41e57
Wijanarko, K. J., Wang, M., & Chow, K. T. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788019958-00303
Investigation of Therapeutic Immune Cell Metabolism
Tueller, J. A. (2019) · ScholarsArchive (Brigham Young University)
High glucose enhances antigen-independent CTL killing via TRAIL
Yang, W., Denger, A., Diener, C., Küppers, F., Soriano‐Baguet, L., Schäfer, G., Yanamandra, A. K., Zhao, R., Knörck, A., Schwarz, E. C., et al. (2021) · Publications of the UdS (Saarland University) · doi:10.22028/d291-35120
Targeting Immune Cell Metabolism for the Improvement of Cancer Therapy
Liu, W. (2022) · International Conference on Biotechnology, Life Science and Medical Engineering (BLSME) · doi:10.23977/blsme.2022037
“Studies have indicated lactic acidosis suppresses PI3K/Akt/mTOR pathway and glycolysis thus impair the proliferation and normal function of T cells [5], [23].”
BackgroundHeath, B. R. (2021) · Deep Blue (University of Michigan) · doi:10.7302/2812
Cancer therapeutics and gut microflora
Ahlawat, S., Asha, A., & Sharma, K. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96128-8.00005-5
1409 Regulation and roles of the polyamine-hypusine axis in CD8+ T-cell fate and functions
Elmarsafawi, A. G., Cleveland, J. L., & Hesterberg, R. S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.1409
T-Cell Metabolism and Its Regulation by Checkpoint Molecules: Consequences for Cancer Immunotherapy
Romero‐Garcia, S., Mendoza, M. S., Carlos‐Reyes, Á., & Prado-García, H. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_159-1
Data from Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells
Drijvers, J. M., Gillis, J. E., Muijlwijk, T., Nguyen, T. H., Gaudiano, E. F., Harris, I. S., LaFleur, M. W., Ringel, A. E., Yao, C.-H., Kurmi, K., et al. (2023) · doi:10.1158/2326-6066.c.6550425
Immune System, Redox Signaling, and Cancer Immunity
Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_6
Combating Immunosuppression within Tumor Microenvironment: A Novel Approach for Drug Design
Mirlekar, B. (2019) · Open Access Journal of Cancer & Oncology · doi:10.23880/oajco-16000144
“…mechanisms by which the TME can hinders efficacy of effector immune response are listed in Table 1/.. Altered cancer cell growth can lead to tumor intrinsic immune suppressive factors, for instance increased level of lactate and regions of hypoxia can inhibit effector T cell functions [15,16].”
Xianbo, W., Yan, F., Xie, Y., Zhu, B., Shi, K., Yu, L., Bi, Y., Zhang, Q., Zeng, X., & Yang, Z. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4784310
T-Cell Metabolism and Its Regulation by Checkpoint Molecules: Consequences for Cancer Immunotherapy
Romero‐Garcia, S., Mendoza, M. S., Carlos‐Reyes, Á., & Prado-García, H. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_159
Additional file 4 of Lipid metabolic features of T cells in the Tumor Microenvironment
Lou, W., Chaoju, 宫. G., Ye, Z., Hu, Y., Zhu, M., Fang, Z., & Xu, H. (2022) · Figshare · doi:10.6084/m9.figshare.21291866
Additional file 2 of Lipid metabolic features of T cells in the Tumor Microenvironment
Lou, W., Chaoju, 宫. G., Ye, Z., Hu, Y., Zhu, M., Fang, Z., & Xu, H. (2022) · Figshare · doi:10.6084/m9.figshare.21291860
Additional file 3 of Lipid metabolic features of T cells in the Tumor Microenvironment
Lou, W., Chaoju, 宫. G., Ye, Z., Hu, Y., Zhu, M., Fang, Z., & Xu, H. (2022) · Figshare · doi:10.6084/m9.figshare.21291863
Dall'olio, F. G. (2023) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.48676/unibo/amsdottorato/10629
Metadata
- Authors
- Sugiura, A., & Rathmell, J. C.
- Affiliations
- Vanderbilt-Ingram Cancer Center (US)
- Corresponding author
- Rathmell, Jeffrey C
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 200
- Issue
- 2
- Pages
- 400-407
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC5777533
- OpenAlex
- W2784164696
- Cited by
- 208
- References
- 89
- Citations by year
- 2026: 22 · 2025: 18 · 2024: 15 · 2023: 30 · 2022: 35 · 2021: 32 · 2020: 29 · 2019: 18 · 2018: 9
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (T32GM007347)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK105550)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- T cell metabolism, tumor microenvironment, tumor-infiltrating T cells, T cell dysfunction, cancer immunotherapy, nutrient consumption, oxygen delivery, oncogenic mutations, cancer therapeutics
- MeSH terms
- Animals, Energy Metabolism, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.